#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=[0010] Continuous stimulation of deep brain structures for the treatment of epilepsy has not met with consistent success.
1-1	0-1	[	_	_	
1-2	1-5	0010	_	_	
1-3	5-6	]	_	_	
1-4	7-17	Continuous	_	_	
1-5	18-29	stimulation	_	_	
1-6	30-32	of	_	_	
1-7	33-37	deep	_	_	
1-8	38-43	brain	_	_	
1-9	44-54	structures	_	_	
1-10	55-58	for	_	_	
1-11	59-62	the	_	_	
1-12	63-72	treatment	_	_	
1-13	73-75	of	_	_	
1-14	76-84	epilepsy	_	_	
1-15	85-88	has	_	_	
1-16	89-92	not	_	_	
1-17	93-96	met	_	_	
1-18	97-101	with	_	_	
1-19	102-112	consistent	_	_	
1-20	113-120	success	_	_	
1-21	120-121	.	_	_	

#Text=To be effective in terminating seizures, it is believed that stimulation should be performed near the focus of the epileptogenic region.
2-1	122-124	To	_	_	
2-2	125-127	be	_	_	
2-3	128-137	effective	_	_	
2-4	138-140	in	_	_	
2-5	141-152	terminating	_	_	
2-6	153-161	seizures	_	_	
2-7	161-162	,	_	_	
2-8	163-165	it	_	_	
2-9	166-168	is	_	_	
2-10	169-177	believed	_	_	
2-11	178-182	that	_	_	
2-12	183-194	stimulation	_	_	
2-13	195-201	should	_	_	
2-14	202-204	be	_	_	
2-15	205-214	performed	_	_	
2-16	215-219	near	_	_	
2-17	220-223	the	_	_	
2-18	224-229	focus	_	_	
2-19	230-232	of	_	_	
2-20	233-236	the	_	_	
2-21	237-250	epileptogenic	_	_	
2-22	251-257	region	_	_	
2-23	257-258	.	_	_	

#Text=The focus is often in the neocortex, where continuous stimulation may cause significant neurological deficit with clinical symptoms, including loss of speech, sensory disorders, or involuntary motion.
3-1	259-262	The	_	_	
3-2	263-268	focus	_	_	
3-3	269-271	is	_	_	
3-4	272-277	often	_	_	
3-5	278-280	in	_	_	
3-6	281-284	the	_	_	
3-7	285-294	neocortex	_	_	
3-8	294-295	,	_	_	
3-9	296-301	where	_	_	
3-10	302-312	continuous	_	_	
3-11	313-324	stimulation	_	_	
3-12	325-328	may	_	_	
3-13	329-334	cause	_	_	
3-14	335-346	significant	_	_	
3-15	347-359	neurological	_	_	
3-16	360-367	deficit	_	_	
3-17	368-372	with	_	_	
3-18	373-381	clinical	_	_	
3-19	382-390	symptoms	_	_	
3-20	390-391	,	_	_	
3-21	392-401	including	_	_	
3-22	402-406	loss	_	_	
3-23	407-409	of	_	_	
3-24	410-416	speech	_	_	
3-25	416-417	,	_	_	
3-26	418-425	sensory	_	_	
3-27	426-435	disorders	_	_	
3-28	435-436	,	_	_	
3-29	437-439	or	_	_	
3-30	440-451	involuntary	_	_	
3-31	452-458	motion	_	_	
3-32	458-459	.	_	_	

#Text=Alternatively, the focus of general seizures may move and would thus require insertion of electrodes where the focus moves.
4-1	460-473	Alternatively	_	_	
4-2	473-474	,	_	_	
4-3	475-478	the	_	_	
4-4	479-484	focus	_	_	
4-5	485-487	of	_	_	
4-6	488-495	general	_	_	
4-7	496-504	seizures	_	_	
4-8	505-508	may	_	_	
4-9	509-513	move	_	_	
4-10	514-517	and	_	_	
4-11	518-523	would	_	_	
4-12	524-528	thus	_	_	
4-13	529-536	require	_	_	
4-14	537-546	insertion	_	_	
4-15	547-549	of	_	_	
4-16	550-560	electrodes	_	_	
4-17	561-566	where	_	_	
4-18	567-570	the	_	_	
4-19	571-576	focus	_	_	
4-20	577-582	moves	_	_	
4-21	582-583	.	_	_	

#Text=This, as well as other conventional treatment modalities, offer some benefit to patients with epilepsy; however, their efficacy is often limited.
#Text=[0011] Accordingly, research has also been directed toward automatic responsive epilepsy treatment based on a detection of imminent seizure.
5-1	584-588	This	_	_	
5-2	588-589	,	_	_	
5-3	590-592	as	_	_	
5-4	593-597	well	_	_	
5-5	598-600	as	_	_	
5-6	601-606	other	_	_	
5-7	607-619	conventional	_	_	
5-8	620-629	treatment	_	_	
5-9	630-640	modalities	_	_	
5-10	640-641	,	_	_	
5-11	642-647	offer	_	_	
5-12	648-652	some	_	_	
5-13	653-660	benefit	_	_	
5-14	661-663	to	_	_	
5-15	664-672	patients	_	_	
5-16	673-677	with	_	_	
5-17	678-686	epilepsy	_	_	
5-18	686-687	;	_	_	
5-19	688-695	however	_	_	
5-20	695-696	,	_	_	
5-21	697-702	their	_	_	
5-22	703-711	efficacy	_	_	
5-23	712-714	is	_	_	
5-24	715-720	often	_	_	
5-25	721-728	limited	_	_	
5-26	728-729	.	_	_	
5-27	730-731	[	_	_	
5-28	731-735	0011	_	_	
5-29	735-736	]	_	_	
5-30	737-748	Accordingly	_	_	
5-31	748-749	,	_	_	
5-32	750-758	research	_	_	
5-33	759-762	has	_	_	
5-34	763-767	also	_	_	
5-35	768-772	been	_	_	
5-36	773-781	directed	_	_	
5-37	782-788	toward	_	_	
5-38	789-798	automatic	_	_	
5-39	799-809	responsive	_	_	
5-40	810-818	epilepsy	_	_	
5-41	819-828	treatment	_	_	
5-42	829-834	based	_	_	
5-43	835-837	on	_	_	
5-44	838-839	a	_	_	
5-45	840-849	detection	_	_	
5-46	850-852	of	_	_	
5-47	853-861	imminent	_	_	
5-48	862-869	seizure	_	_	
5-49	869-870	.	_	_	

#Text=Neuropace, Inc. is presently developing and conducting clinical trials on an implantable responsive neurostimulator for epilepsy.
6-1	871-880	Neuropace	_	_	
6-2	880-881	,	_	_	
6-3	882-885	Inc	_	_	
6-4	885-886	.	_	_	
6-5	887-889	is	_	_	
6-6	890-899	presently	_	_	
6-7	900-910	developing	_	_	
6-8	911-914	and	_	_	
6-9	915-925	conducting	_	_	
6-10	926-934	clinical	_	_	
6-11	935-941	trials	_	_	
6-12	942-944	on	_	_	
6-13	945-947	an	_	_	
6-14	948-959	implantable	_	_	
6-15	960-970	responsive	_	_	
6-16	971-986	neurostimulator	_	_	
6-17	987-990	for	_	_	
6-18	991-999	epilepsy	_	_	
6-19	999-1000	.	_	_	

#Text=Once again, there are the risks involved with an implantable system.
7-1	1001-1005	Once	_	_	
7-2	1006-1011	again	_	_	
7-3	1011-1012	,	_	_	
7-4	1013-1018	there	_	_	
7-5	1019-1022	are	_	_	
7-6	1023-1026	the	_	_	
7-7	1027-1032	risks	_	_	
7-8	1033-1041	involved	_	_	
7-9	1042-1046	with	_	_	
7-10	1047-1049	an	_	_	
7-11	1050-1061	implantable	_	_	
7-12	1062-1068	system	_	_	
7-13	1068-1069	.	_	_	

#Text=For episodes where the focus of the seizure moves, or where there is no clear focus, it would be nearly impossible to place electrodes in every location where a seizure focus may be.
8-1	1070-1073	For	_	_	
8-2	1074-1082	episodes	_	_	
8-3	1083-1088	where	_	_	
8-4	1089-1092	the	_	_	
8-5	1093-1098	focus	_	_	
8-6	1099-1101	of	_	_	
8-7	1102-1105	the	_	_	
8-8	1106-1113	seizure	_	_	
8-9	1114-1119	moves	_	_	
8-10	1119-1120	,	_	_	
8-11	1121-1123	or	_	_	
8-12	1124-1129	where	_	_	
8-13	1130-1135	there	_	_	
8-14	1136-1138	is	_	_	
8-15	1139-1141	no	_	_	
8-16	1142-1147	clear	_	_	
8-17	1148-1153	focus	_	_	
8-18	1153-1154	,	_	_	
8-19	1155-1157	it	_	_	
8-20	1158-1163	would	_	_	
8-21	1164-1166	be	_	_	
8-22	1167-1173	nearly	_	_	
8-23	1174-1184	impossible	_	_	
8-24	1185-1187	to	_	_	
8-25	1188-1193	place	_	_	
8-26	1194-1204	electrodes	_	_	
8-27	1205-1207	in	_	_	
8-28	1208-1213	every	_	_	
8-29	1214-1222	location	_	_	
8-30	1223-1228	where	_	_	
8-31	1229-1230	a	_	_	
8-32	1231-1238	seizure	_	_	
8-33	1239-1244	focus	_	_	
8-34	1245-1248	may	_	_	
8-35	1249-1251	be	_	_	
8-36	1251-1252	.	_	_	

#Text=Compromises must be made to minimize the number of implanted electrodes and maximize the efficacy.
9-1	1253-1264	Compromises	_	_	
9-2	1265-1269	must	_	_	
9-3	1270-1272	be	_	_	
9-4	1273-1277	made	_	_	
9-5	1278-1280	to	_	_	
9-6	1281-1289	minimize	_	_	
9-7	1290-1293	the	_	_	
9-8	1294-1300	number	_	_	
9-9	1301-1303	of	_	_	
9-10	1304-1313	implanted	_	_	
9-11	1314-1324	electrodes	_	_	
9-12	1325-1328	and	_	_	
9-13	1329-1337	maximize	_	_	
9-14	1338-1341	the	_	_	
9-15	1342-1350	efficacy	_	_	
9-16	1350-1351	.	_	_	

#Text=Another major concern is that such a device cannot be implanted quick enough during an emergency seizure that is pharmaco-resistant.
#Text=[0012] Trigeminal nerve stimulation is also a possible method for desynchronizing seizure activity.
10-1	1352-1359	Another	_	_	
10-2	1360-1365	major	_	_	
10-3	1366-1373	concern	_	_	
10-4	1374-1376	is	_	_	
10-5	1377-1381	that	_	_	
10-6	1382-1386	such	_	_	
10-7	1387-1388	a	_	_	
10-8	1389-1395	device	_	_	
10-9	1396-1402	cannot	_	_	
10-10	1403-1405	be	_	_	
10-11	1406-1415	implanted	_	_	
10-12	1416-1421	quick	_	_	
10-13	1422-1428	enough	_	_	
10-14	1429-1435	during	_	_	
10-15	1436-1438	an	_	_	
10-16	1439-1448	emergency	_	_	
10-17	1449-1456	seizure	_	_	
10-18	1457-1461	that	_	_	
10-19	1462-1464	is	_	_	
10-20	1465-1483	pharmaco-resistant	_	_	
10-21	1483-1484	.	_	_	
10-22	1485-1486	[	_	_	
10-23	1486-1490	0012	_	_	
10-24	1490-1491	]	_	_	
10-25	1492-1502	Trigeminal	*[1]	13-4[2_1]	
10-26	1503-1508	nerve	*[1]	_	
10-27	1509-1520	stimulation	*[1]	_	
10-28	1521-1523	is	_	_	
10-29	1524-1528	also	_	_	
10-30	1529-1530	a	_	_	
10-31	1531-1539	possible	_	_	
10-32	1540-1546	method	_	_	
10-33	1547-1550	for	_	_	
10-34	1551-1566	desynchronizing	_	_	
10-35	1567-1574	seizure	_	_	
10-36	1575-1583	activity	_	_	
10-37	1583-1584	.	_	_	

#Text=Advanced Bionics, Inc. is currently developing an implantable device for the treatment of epilepsy that involves the application of electrical stimulation to the trigemnial nerve.
11-1	1585-1593	Advanced	_	_	
11-2	1594-1601	Bionics	_	_	
11-3	1601-1602	,	_	_	
11-4	1603-1606	Inc	_	_	
11-5	1606-1607	.	_	_	
11-6	1608-1610	is	_	_	
11-7	1611-1620	currently	_	_	
11-8	1621-1631	developing	_	_	
11-9	1632-1634	an	_	_	
11-10	1635-1646	implantable	_	_	
11-11	1647-1653	device	_	_	
11-12	1654-1657	for	_	_	
11-13	1658-1661	the	_	_	
11-14	1662-1671	treatment	_	_	
11-15	1672-1674	of	_	_	
11-16	1675-1683	epilepsy	_	_	
11-17	1684-1688	that	_	_	
11-18	1689-1697	involves	_	_	
11-19	1698-1701	the	_	_	
11-20	1702-1713	application	_	_	
11-21	1714-1716	of	_	_	
11-22	1717-1727	electrical	_	_	
11-23	1728-1739	stimulation	_	_	
11-24	1740-1742	to	_	_	
11-25	1743-1746	the	_	_	
11-26	1747-1757	trigemnial	_	_	
11-27	1758-1763	nerve	_	_	
11-28	1763-1764	.	_	_	

#Text=As with the vagus nerve, the trigeminal nerve does not project to all areas of the brain and cannot stop all seizures.
12-1	1765-1767	As	_	_	
12-2	1768-1772	with	_	_	
12-3	1773-1776	the	_	_	
12-4	1777-1782	vagus	_	_	
12-5	1783-1788	nerve	_	_	
12-6	1788-1789	,	_	_	
12-7	1790-1793	the	_	_	
12-8	1794-1804	trigeminal	_	_	
12-9	1805-1810	nerve	_	_	
12-10	1811-1815	does	_	_	
12-11	1816-1819	not	_	_	
12-12	1820-1827	project	_	_	
12-13	1828-1830	to	_	_	
12-14	1831-1834	all	_	_	
12-15	1835-1840	areas	_	_	
12-16	1841-1843	of	_	_	
12-17	1844-1847	the	_	_	
12-18	1848-1853	brain	_	_	
12-19	1854-1857	and	_	_	
12-20	1858-1864	cannot	_	_	
12-21	1865-1869	stop	_	_	
12-22	1870-1873	all	_	_	
12-23	1874-1882	seizures	_	_	
12-24	1882-1883	.	_	_	

#Text=Once again, this method will have the same concerns for implantable devices as with the above-mentioned devices.
#Text=[0013] There has been only one anecdotal report in the literature about electroconvulsive therapy (ECT) use in medically intractable seizures in human patients (Griesemer et al., Neurology; 1997 49(5):1389-92): one patient experienced "change in a seizure pattern with cessation at higher intensity," while the other experienced "decrease in spontaneous seizure frequency".
13-1	1884-1888	Once	_	_	
13-2	1889-1894	again	_	_	
13-3	1894-1895	,	_	_	
13-4	1896-1900	this	*[2]	_	
13-5	1901-1907	method	*[2]	_	
13-6	1908-1912	will	_	_	
13-7	1913-1917	have	_	_	
13-8	1918-1921	the	_	_	
13-9	1922-1926	same	_	_	
13-10	1927-1935	concerns	_	_	
13-11	1936-1939	for	_	_	
13-12	1940-1951	implantable	_	_	
13-13	1952-1959	devices	_	_	
13-14	1960-1962	as	_	_	
13-15	1963-1967	with	_	_	
13-16	1968-1971	the	_	_	
13-17	1972-1987	above-mentioned	_	_	
13-18	1988-1995	devices	_	_	
13-19	1995-1996	.	_	_	
13-20	1997-1998	[	_	_	
13-21	1998-2002	0013	_	_	
13-22	2002-2003	]	_	_	
13-23	2004-2009	There	_	_	
13-24	2010-2013	has	_	_	
13-25	2014-2018	been	_	_	
13-26	2019-2023	only	_	_	
13-27	2024-2027	one	_	_	
13-28	2028-2037	anecdotal	_	_	
13-29	2038-2044	report	_	_	
13-30	2045-2047	in	_	_	
13-31	2048-2051	the	_	_	
13-32	2052-2062	literature	_	_	
13-33	2063-2068	about	_	_	
13-34	2069-2086	electroconvulsive	_	_	
13-35	2087-2094	therapy	_	_	
13-36	2095-2096	(	_	_	
13-37	2096-2099	ECT	_	_	
13-38	2099-2100	)	_	_	
13-39	2101-2104	use	_	_	
13-40	2105-2107	in	_	_	
13-41	2108-2117	medically	_	_	
13-42	2118-2129	intractable	_	_	
13-43	2130-2138	seizures	_	_	
13-44	2139-2141	in	_	_	
13-45	2142-2147	human	_	_	
13-46	2148-2156	patients	_	_	
13-47	2157-2158	(	_	_	
13-48	2158-2167	Griesemer	_	_	
13-49	2168-2170	et	_	_	
13-50	2171-2173	al	_	_	
13-51	2173-2174	.	_	_	
13-52	2174-2175	,	_	_	
13-53	2176-2185	Neurology	_	_	
13-54	2185-2186	;	_	_	
13-55	2187-2191	1997	_	_	
13-56	2192-2194	49	_	_	
13-57	2194-2195	(	_	_	
13-58	2195-2196	5	_	_	
13-59	2196-2197	)	_	_	
13-60	2197-2198	:	_	_	
13-61	2198-2202	1389	_	_	
13-62	2202-2203	-	_	_	
13-63	2203-2205	92	_	_	
13-64	2205-2206	)	_	_	
13-65	2206-2207	:	_	_	
13-66	2208-2211	one	_	_	
13-67	2212-2219	patient	_	_	
13-68	2220-2231	experienced	_	_	
13-69	2232-2233	"	_	_	
13-70	2233-2239	change	_	_	
13-71	2240-2242	in	_	_	
13-72	2243-2244	a	_	_	
13-73	2245-2252	seizure	_	_	
13-74	2253-2260	pattern	_	_	
13-75	2261-2265	with	_	_	
13-76	2266-2275	cessation	_	_	
13-77	2276-2278	at	_	_	
13-78	2279-2285	higher	_	_	
13-79	2286-2295	intensity	_	_	
13-80	2295-2296	,	_	_	
13-81	2296-2297	"	_	_	
13-82	2298-2303	while	_	_	
13-83	2304-2307	the	_	_	
13-84	2308-2313	other	_	_	
13-85	2314-2325	experienced	_	_	
13-86	2326-2327	"	_	_	
13-87	2327-2335	decrease	_	_	
13-88	2336-2338	in	_	_	
13-89	2339-2350	spontaneous	_	_	
13-90	2351-2358	seizure	_	_	
13-91	2359-2368	frequency	_	_	
13-92	2368-2369	"	_	_	
13-93	2369-2370	.	_	_	

#Text=Surprisingly, no further studies to investigate this methodology in an animal model or in a human clinical series are found.
14-1	2371-2383	Surprisingly	_	_	
14-2	2383-2384	,	_	_	
14-3	2385-2387	no	_	_	
14-4	2388-2395	further	_	_	
14-5	2396-2403	studies	_	_	
14-6	2404-2406	to	_	_	
14-7	2407-2418	investigate	_	_	
14-8	2419-2423	this	_	_	
14-9	2424-2435	methodology	_	_	
14-10	2436-2438	in	_	_	
14-11	2439-2441	an	_	_	
14-12	2442-2448	animal	_	_	
14-13	2449-2454	model	_	_	
14-14	2455-2457	or	_	_	
14-15	2458-2460	in	_	_	
14-16	2461-2462	a	_	_	
14-17	2463-2468	human	_	_	
14-18	2469-2477	clinical	_	_	
14-19	2478-2484	series	_	_	
14-20	2485-2488	are	_	_	
14-21	2489-2494	found	_	_	
14-22	2494-2495	.	_	_	

#Text=Electroconvulsive therapy (ECT) is performed using conventional EEG electrodes that are not capable of focusing stimulation to a specific volume of biological tissue.
15-1	2496-2513	Electroconvulsive	_	_	
15-2	2514-2521	therapy	_	_	
15-3	2522-2523	(	_	_	
15-4	2523-2526	ECT	_	_	
15-5	2526-2527	)	_	_	
15-6	2528-2530	is	_	_	
15-7	2531-2540	performed	_	_	
15-8	2541-2546	using	_	_	
15-9	2547-2559	conventional	_	_	
15-10	2560-2563	EEG	_	_	
15-11	2564-2574	electrodes	_	_	
15-12	2575-2579	that	_	_	
15-13	2580-2583	are	_	_	
15-14	2584-2587	not	_	_	
15-15	2588-2595	capable	_	_	
15-16	2596-2598	of	_	_	
15-17	2599-2607	focusing	_	_	
15-18	2608-2619	stimulation	_	_	
15-19	2620-2622	to	_	_	
15-20	2623-2624	a	_	_	
15-21	2625-2633	specific	_	_	
15-22	2634-2640	volume	_	_	
15-23	2641-2643	of	_	_	
15-24	2644-2654	biological	_	_	
15-25	2655-2661	tissue	_	_	
15-26	2661-2662	.	_	_	

#Text=To perform ECT, strong muscle relaxants, as well as sedation, are often used.
16-1	2663-2665	To	_	_	
16-2	2666-2673	perform	_	_	
16-3	2674-2677	ECT	_	_	
16-4	2677-2678	,	_	_	
16-5	2679-2685	strong	_	_	
16-6	2686-2692	muscle	_	_	
16-7	2693-2702	relaxants	_	_	
16-8	2702-2703	,	_	_	
16-9	2704-2706	as	_	_	
16-10	2707-2711	well	_	_	
16-11	2712-2714	as	_	_	
16-12	2715-2723	sedation	_	_	
16-13	2723-2724	,	_	_	
16-14	2725-2728	are	_	_	
16-15	2729-2734	often	_	_	
16-16	2735-2739	used	_	_	
16-17	2739-2740	.	_	_	

#Text=Thus, the patient must be monitored closely.
#Text=[0014] It has been proposed that if one can apply electrical stimulation at or near the foci, the origin of epileptiform activity, the efficacy of seizure control will be increased.
17-1	2741-2745	Thus	_	_	
17-2	2745-2746	,	_	_	
17-3	2747-2750	the	_	_	
17-4	2751-2758	patient	_	_	
17-5	2759-2763	must	_	_	
17-6	2764-2766	be	_	_	
17-7	2767-2776	monitored	_	_	
17-8	2777-2784	closely	_	_	
17-9	2784-2785	.	_	_	
17-10	2786-2787	[	_	_	
17-11	2787-2791	0014	_	_	
17-12	2791-2792	]	_	_	
17-13	2793-2795	It	_	_	
17-14	2796-2799	has	_	_	
17-15	2800-2804	been	_	_	
17-16	2805-2813	proposed	_	_	
17-17	2814-2818	that	_	_	
17-18	2819-2821	if	_	_	
17-19	2822-2825	one	_	_	
17-20	2826-2829	can	_	_	
17-21	2830-2835	apply	_	_	
17-22	2836-2846	electrical	_	_	
17-23	2847-2858	stimulation	_	_	
17-24	2859-2861	at	_	_	
17-25	2862-2864	or	_	_	
17-26	2865-2869	near	_	_	
17-27	2870-2873	the	_	_	
17-28	2874-2878	foci	_	_	
17-29	2878-2879	,	_	_	
17-30	2880-2883	the	_	_	
17-31	2884-2890	origin	_	_	
17-32	2891-2893	of	_	_	
17-33	2894-2906	epileptiform	_	_	
17-34	2907-2915	activity	_	_	
17-35	2915-2916	,	_	_	
17-36	2917-2920	the	_	_	
17-37	2921-2929	efficacy	_	_	
17-38	2930-2932	of	_	_	
17-39	2933-2940	seizure	_	_	
17-40	2941-2948	control	_	_	
17-41	2949-2953	will	_	_	
17-42	2954-2956	be	_	_	
17-43	2957-2966	increased	_	_	
17-44	2966-2967	.	_	_	

#Text=Finding the seizure foci usually involves very expensive and immobile imaging equipment, such as a functional magnetic resonance (fMRI) system.
18-1	2968-2975	Finding	_	_	
18-2	2976-2979	the	_	_	
18-3	2980-2987	seizure	_	_	
18-4	2988-2992	foci	_	_	
18-5	2993-3000	usually	_	_	
18-6	3001-3009	involves	_	_	
18-7	3010-3014	very	_	_	
18-8	3015-3024	expensive	_	_	
18-9	3025-3028	and	_	_	
18-10	3029-3037	immobile	_	_	
18-11	3038-3045	imaging	_	_	
18-12	3046-3055	equipment	_	_	
18-13	3055-3056	,	_	_	
18-14	3057-3061	such	_	_	
18-15	3062-3064	as	_	_	
18-16	3065-3066	a	_	_	
18-17	3067-3077	functional	_	_	
18-18	3078-3086	magnetic	_	_	
18-19	3087-3096	resonance	_	_	
18-20	3097-3098	(	_	_	
18-21	3098-3102	fMRI	_	_	
18-22	3102-3103	)	_	_	
18-23	3104-3110	system	_	_	
18-24	3110-3111	.	_	_	

#Text=Even with such an elaborate system, real-time analysis of the seizure activity still cannot be achieved.
19-1	3112-3116	Even	_	_	
19-2	3117-3121	with	_	_	
19-3	3122-3126	such	_	_	
19-4	3127-3129	an	_	_	
19-5	3130-3139	elaborate	_	_	
19-6	3140-3146	system	_	_	
19-7	3146-3147	,	_	_	
19-8	3148-3157	real-time	_	_	
19-9	3158-3166	analysis	_	_	
19-10	3167-3169	of	_	_	
19-11	3170-3173	the	_	_	
19-12	3174-3181	seizure	_	_	
19-13	3182-3190	activity	_	_	
19-14	3191-3196	still	_	_	
19-15	3197-3203	cannot	_	_	
19-16	3204-3206	be	_	_	
19-17	3207-3215	achieved	_	_	
19-18	3215-3216	.	_	_	

#Text=Another means for seizure foci localization is to drill holes into the cranium, and insert electrodes to record and analyze the electrical activity from the brain to determine the location of the foci.
20-1	3217-3224	Another	_	_	
20-2	3225-3230	means	_	_	
20-3	3231-3234	for	_	_	
20-4	3235-3242	seizure	_	_	
20-5	3243-3247	foci	_	_	
20-6	3248-3260	localization	_	_	
20-7	3261-3263	is	_	_	
20-8	3264-3266	to	_	_	
20-9	3267-3272	drill	_	_	
20-10	3273-3278	holes	_	_	
20-11	3279-3283	into	_	_	
20-12	3284-3287	the	_	_	
20-13	3288-3295	cranium	_	_	
20-14	3295-3296	,	_	_	
20-15	3297-3300	and	_	_	
20-16	3301-3307	insert	_	_	
20-17	3308-3318	electrodes	_	_	
20-18	3319-3321	to	_	_	
20-19	3322-3328	record	_	_	
20-20	3329-3332	and	_	_	
20-21	3333-3340	analyze	_	_	
20-22	3341-3344	the	_	_	
20-23	3345-3355	electrical	_	_	
20-24	3356-3364	activity	_	_	
20-25	3365-3369	from	_	_	
20-26	3370-3373	the	_	_	
20-27	3374-3379	brain	_	_	
20-28	3380-3382	to	_	_	
20-29	3383-3392	determine	_	_	
20-30	3393-3396	the	_	_	
20-31	3397-3405	location	_	_	
20-32	3406-3408	of	_	_	
20-33	3409-3412	the	_	_	
20-34	3413-3417	foci	_	_	
20-35	3417-3418	.	_	_	

#Text=The latter technique is extremely invasive, requires a neurosurgeon, and can lead to complications.
21-1	3419-3422	The	_	_	
21-2	3423-3429	latter	_	_	
21-3	3430-3439	technique	_	_	
21-4	3440-3442	is	_	_	
21-5	3443-3452	extremely	_	_	
21-6	3453-3461	invasive	_	_	
21-7	3461-3462	,	_	_	
21-8	3463-3471	requires	_	_	
21-9	3472-3473	a	_	_	
21-10	3474-3486	neurosurgeon	_	_	
21-11	3486-3487	,	_	_	
21-12	3488-3491	and	_	_	
21-13	3492-3495	can	_	_	
21-14	3496-3500	lead	_	_	
21-15	3501-3503	to	_	_	
21-16	3504-3517	complications	_	_	
21-17	3517-3518	.	_	_	

#Text=Similar techniques are applicable for the treatment of Parkinson's disease and other neurological disorders.
22-1	3519-3526	Similar	_	_	
22-2	3527-3537	techniques	_	_	
22-3	3538-3541	are	_	_	
22-4	3542-3552	applicable	_	_	
22-5	3553-3556	for	_	_	
22-6	3557-3560	the	_	_	
22-7	3561-3570	treatment	_	_	
22-8	3571-3573	of	_	_	
22-9	3574-3585	Parkinson's	_	_	
22-10	3586-3593	disease	_	_	
22-11	3594-3597	and	_	_	
22-12	3598-3603	other	_	_	
22-13	3604-3616	neurological	_	_	
22-14	3617-3626	disorders	_	_	
22-15	3626-3627	.	_	_	

#Text=Another problem that neither of these techniques can overcome is that the foci may move to various other locations.
23-1	3628-3635	Another	_	_	
23-2	3636-3643	problem	_	_	
23-3	3644-3648	that	_	_	
23-4	3649-3656	neither	_	_	
23-5	3657-3659	of	_	_	
23-6	3660-3665	these	_	_	
23-7	3666-3676	techniques	_	_	
23-8	3677-3680	can	_	_	
23-9	3681-3689	overcome	_	_	
23-10	3690-3692	is	_	_	
23-11	3693-3697	that	_	_	
23-12	3698-3701	the	_	_	
23-13	3702-3706	foci	_	_	
23-14	3707-3710	may	_	_	
23-15	3711-3715	move	_	_	
23-16	3716-3718	to	_	_	
23-17	3719-3726	various	_	_	
23-18	3727-3732	other	_	_	
23-19	3733-3742	locations	_	_	
23-20	3742-3743	.	_	_	

#Text=The fMRI and other similar imaging systems, such as positron emission tomography (PET), depend on blood flow changes, which can take many seconds to minutes to occur and thus unable to capture images of fast changing brain activity.
24-1	3744-3747	The	_	_	
24-2	3748-3752	fMRI	_	_	
24-3	3753-3756	and	_	_	
24-4	3757-3762	other	_	_	
24-5	3763-3770	similar	_	_	
24-6	3771-3778	imaging	_	_	
24-7	3779-3786	systems	_	_	
24-8	3786-3787	,	_	_	
24-9	3788-3792	such	_	_	
24-10	3793-3795	as	_	_	
24-11	3796-3804	positron	_	_	
24-12	3805-3813	emission	_	_	
24-13	3814-3824	tomography	_	_	
24-14	3825-3826	(	_	_	
24-15	3826-3829	PET	_	_	
24-16	3829-3830	)	_	_	
24-17	3830-3831	,	_	_	
24-18	3832-3838	depend	_	_	
24-19	3839-3841	on	_	_	
24-20	3842-3847	blood	_	_	
24-21	3848-3852	flow	_	_	
24-22	3853-3860	changes	_	_	
24-23	3860-3861	,	_	_	
24-24	3862-3867	which	_	_	
24-25	3868-3871	can	_	_	
24-26	3872-3876	take	_	_	
24-27	3877-3881	many	_	_	
24-28	3882-3889	seconds	_	_	
24-29	3890-3892	to	_	_	
24-30	3893-3900	minutes	_	_	
24-31	3901-3903	to	_	_	
24-32	3904-3909	occur	_	_	
24-33	3910-3913	and	_	_	
24-34	3914-3918	thus	_	_	
24-35	3919-3925	unable	_	_	
24-36	3926-3928	to	_	_	
24-37	3929-3936	capture	_	_	
24-38	3937-3943	images	_	_	
24-39	3944-3946	of	_	_	
24-40	3947-3951	fast	_	_	
24-41	3952-3960	changing	_	_	
24-42	3961-3966	brain	_	_	
24-43	3967-3975	activity	_	_	
24-44	3975-3976	.	_	_	

#Text=A moving seizure focus is at best difficult to map with electrodes inserted into the brain; it may take many electrodes and many holes in the cranium to track the moving foci.
25-1	3977-3978	A	_	_	
25-2	3979-3985	moving	_	_	
25-3	3986-3993	seizure	_	_	
25-4	3994-3999	focus	_	_	
25-5	4000-4002	is	_	_	
25-6	4003-4005	at	_	_	
25-7	4006-4010	best	_	_	
25-8	4011-4020	difficult	_	_	
25-9	4021-4023	to	_	_	
25-10	4024-4027	map	_	_	
25-11	4028-4032	with	_	_	
25-12	4033-4043	electrodes	_	_	
25-13	4044-4052	inserted	_	_	
25-14	4053-4057	into	_	_	
25-15	4058-4061	the	_	_	
25-16	4062-4067	brain	_	_	
25-17	4067-4068	;	_	_	
25-18	4069-4071	it	_	_	
25-19	4072-4075	may	_	_	
25-20	4076-4080	take	_	_	
25-21	4081-4085	many	_	_	
25-22	4086-4096	electrodes	_	_	
25-23	4097-4100	and	_	_	
25-24	4101-4105	many	_	_	
25-25	4106-4111	holes	_	_	
25-26	4112-4114	in	_	_	
25-27	4115-4118	the	_	_	
25-28	4119-4126	cranium	_	_	
25-29	4127-4129	to	_	_	
25-30	4130-4135	track	_	_	
25-31	4136-4139	the	_	_	
25-32	4140-4146	moving	_	_	
25-33	4147-4151	foci	_	_	
25-34	4151-4152	.	_	_	
